Comparison of ESC and ACCF/AHA Guidelines for Oral Antiplatelet Treatment in the Management of Patients with Acute Coronary Syndrome

Basically, acute coronary syndrome (ACS) is caused by the partial or total occlusion of coronary arteries because of platelet activation and aggregation. Hence, one of the major components of ACS treatment is the inhibition of platelet activation and aggregation. New studies performed in recent year...

Full description

Bibliographic Details
Published in:Eurasian Journal of Emergency Medicine
Main Authors: Ayhan Sarıtaş, Harun Güneş
Format: Article
Language:English
Published: Emergency Medicine Physicians’ Association of Turkey 2016-09-01
Subjects:
Acute coronary syndrome
recommendations
aspirin
prasugrel
ticagrelor
clopidogrel
Online Access: http://akademikaciltip.com/archives/archive-detail/article-preview/comparison-of-esc-and-accf-aha-guidelines-for-oral/21815
Description
Summary:Basically, acute coronary syndrome (ACS) is caused by the partial or total occlusion of coronary arteries because of platelet activation and aggregation. Hence, one of the major components of ACS treatment is the inhibition of platelet activation and aggregation. New studies performed in recent years have led to the update of guidelines for the usage of antiplatelet agents (APA) in the treatment of ACSs. This paper aims to compare the European Society of Cardiology (ESC) and American Heart Association (ACCF/AHA) guidelines, by summarizing the key points, regarding the usage of oral APA in patients admitted to emergency departments due to ACS.
ISSN:2149-5807
2149-6048

Similar Items